Table 2.
Summarized Pathologic Variables of All Patient Groups
| Untreated |
DAA-SVR |
P Valuea | P Valueb | |||||
|---|---|---|---|---|---|---|---|---|
| −CC (n = 52) | +HCC (n = 13) | Total (n = 65) | −CC (n = 12) | +HCC (n = 19) | Total (n = 31) | |||
|
| ||||||||
| Inflammatory grade, No. (%) | ||||||||
| 0 | 1 (2) | 0 | 1 (2) | 2 (17) | 2 (10) | 4 (13) | .04c | .45 |
| 1 | 27 (52) | 2 (15) | 29 (45) | 8 (67) | 10 (53) | 18 (58) | ||
| 2 | 19 (37) | 8 (62) | 27 (41) | 1 (8) | 6 (32) | 7 (23) | ||
| 3 | 5 (10) | 3 (23) | 8 (12) | 1 (8) | 1 (5) | 2 (6) | ||
| High inflammatory grade (2 or 3), No. (%) | 24 (46) | 11 (85) | 35 (53) | 2 (17) | 7 (37) | 9 (29) | .04c | .10 |
| Fibrosis stage, No. (%) | ||||||||
| 0 | 3 (6) | 0 | 3 (4) | 0 | 0 | 0 | ||
| 1 | 9 (17) | 0 | 9 (14) | 0 | 0 | 0 | ||
| 2 | 15 (29) | 1 (8) | 16 (25) | 5 (42) | 3 (16) | 8 (26) | ||
| 3 | 7 (13) | 2 (15) | 9 (14) | 0 | 2 (10) | 2 (6) | ||
| 4 | 18 (35) | 10 (77) | 28 (43) | 7 (58) | 14 (74) | 21 (68) | ||
| Advanced fibrosis (stage 3 or 4), No. (%) | 25 (48) | 12 (92) | 37 (57) | 7 (58) | 16 (84) | 23 (74) | .12 | <.001c |
| PIR score, No. (%)d | .54 | .04c | ||||||
| P | 7 (42) | 5 (56) | 12 (46) | 4 (57) | 4 (29) | 8 (38) | ||
| I | 5 (29) | 4 (44) | 9 (35) | 0 (0) | 6 (43) | 6 (29) | ||
| R | 5 (29) | 0 | 5 (19) | 3 (43) | 4 (29) | 7 (33) | ||
| P or I | 12 (71) | 9 (100) | 21 (81) | 4 (57) | 10 (71) | 14 (67) | .33 | .08 |
Abbreviations: DAA-SVR, direct acting antiviral–induced sustained viral response; −CC, no hepatocellular carcinoma; +HCC, with hepatocellular carcinoma; PIR, progressive, indeterminate, regressive.
a
P values in this column correspond to tests comparing DAA-SVR versus untreated patients.
b
P values in this column correspond to tests comparing +HCC versus no-HCC patients.
c
Significant P value (< .05).
d
Two cases of stage 4 cirrhosis were not analyzed for PIR because of (1) 1 being a consult slide that was sent back to the original institution, and (2) material considered inadequate for analysis.